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Abstract 
BACKGROUND: Thyroid uptake of technetium-99m methoxyisobutylisonitrile (
99m
Tc-MIBI) during parathyroid 
scintigraphy can be affected by various conditions. 
AIM: To evaluate the frequency of absent 
99m
Tc-MIBI uptake by the thyroid gland in the early phase of dual-phase 
parathyroid scintigraphy. 
METHODS: The early planar images of dual phase Tc
99m
 MIBI parathyroid scintigraphy from 217 patients 
performed between 2014 and 2017 were retrospectively analysed. Patients were divided into two groups. The first 
group included 147 patients with primary hyperparathyroidism and the second group included 70 patients with 
chronic renal failure. Patient records, laboratory and ultrasonographic data were analysed in all patients. 
Descriptive statistic was used for data analysis. 
RESULTS: Out of all patients in the first group, 18 patients (12.24%) showed absent thyroid uptake. 
Thyroidectomy was performed in 44.4% of these patients, and the rest of them had some thyroid disease. Only 
one patient had no thyroid or another chronic disease. In the second group, 8 patients (11.42%) presented with 
absent thyroid uptake of MIBI. Among them, 5 patients had no history of thyroid disease and had been on 
hemodialysis programme, and 3 patients had hypothyroidism. 
CONCLUSION: Absent 
99m
Tc-MIBI uptake in the thyroid during the early phase of parathyroid scintigraphy is most 
frequently related to thyroid disease. A small proportion of patients with chronic renal failure can present with 
absent 
99m
Tc-MIBI uptake in the thyroid as well. The mechanism for this alteration is still unclear and needs further 
investigation. 
 
 
 
 
Introduction 
 
Parathyroid scintigraphy is an imaging 
modality used in the diagnosis and preoperative 
localisation of parathyroid adenomas or hyperplastic 
parathyroid glands in patients with 
hyperparathyroidism. Several protocols are used for 
this purpose: Dual-phase single isotope imaging, 
single phase dual-isotope subtraction method or a 
combination of the two [1] [2]. Most commonly used 
method in clinical practice nowadays is Dual-phase 
technetium-99m methoxyisobutylisonitrile (
99m
Tc-MIBI) 
scintigraphy because of its high specificity and 
simplicity, despite the low sensitivity for detection of 
very small adenomas.  
MIBI is a lipophilic, monovalent, cationic 
complex. The uptake by parathyroid tumours was first 
published in 1989 by Coakley et al., [3]. MIBI is 
distributed proportionally to blood flow in the body and 
is sequestered intracellularly within the mitochondria 
by passive diffusion in cells with negative 
transmembrane potential. The slower MIBI washout 
from the parathyroid adenomas and hyperplastic 
glands compared with the normal thyroid and 
parathyroid tissue provides the possibility for the use 
of this radiopharmaceutical for this kind of imaging. 
The main pathophysiological mechanism for slower 
MIBI washout from the parathyroid adenomas lies 
within the increased number of mitochondria in 
hyperactive parathyroid cells [4]. Several factors can 
influence the normal distribution of 
99m
Tc-MIBI in the 
early phase of the scanning in the thyroid and 
parathyroid glands. Awareness about variations in the 
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biodistribution of MIBI is important for the proper 
interpretation of the scan results. Diminished MIBI 
uptake in the thyroid and parathyroid adenomas is 
reported in several studies [5] [6]. Our study aimed to 
evaluate the frequency of absent 
99m
Tc-MIBI uptake 
by the thyroid gland in the early phase of dual-phase 
parathyroid scintigraphy in patients with primary 
hyperparathyroidism and patients with secondary 
hyperparathyroidism due to chronic renal failure.  
 
 
Material and Methods 
 
Retrospective analysis of 278 parathyroid 
scintigraphies from 217 patients (151 females 66 
males, aged 16 to 82 years, and mean age 54.7 ± 
14.13) from the archive of the Institute of 
Pathophysiology and Nuclear Medicine at the Medical 
Faculty in Skopje was performed. The scintigraphies 
were performed under the same protocol in the period 
from January 2014–June 2017. Patients were divided 
into two groups. The first group included 147 patients, 
119 females 28 males, age range 16-78 years (mean 
age 55.9 ± 12.75), referred for investigation of primary 
hyperparathyroidism and the second group included 
70 patients, 32 females 38 males, age range 16-82 
years (mean age 53 ± 14.58), referred with diagnosis 
of secondary hyperparathyroidism due to chronic 
renal failure. The parathyroid scintigraphy was 
performed after IV injection of 740 MBq 
99m
Tc-MIBI. 
Early scans of the neck and the upper thorax were 
obtained 10 minutes after injection with a planar 
gamma camera in AP view (MEDISO-DHV) with low 
energy, general purpose collimator (LEGP) and 128 x 
128 matrix. Late planar scans were obtained 2 hours 
after injection.  
Some patients had SPECT/CT (OPTIMA 
NM/CT 640, GE Healthcare) performed in the delayed 
phase. Thirty 15-second images were taken by each 
head over 180-degree stepwise rotation and stored in 
a 128*128 matrix of a frame mode. All patients had 
thyroid ultrasound performed at our Institution with a 
high-resolution broadband linear array transducer (LN 
12-3, Philips HD6) to verify the presence/ absence of 
parathyroid adenoma and to exclude the presence of 
thyroid nodules or other focal lesions in the thyroid 
gland.  
All scans were evaluated for 
99m
Tc-MIBI 
uptake in the thyroid gland in the early phase (thyroid 
phase) qualitatively by 2 nuclear medicine specialists 
blinded to patient data. The patients’ groups were 
further subdivided according to these findings. The 
patients from the first group with a normal distribution 
of 
99m
Tc-MIBI were classified as group 1a, and the 
patients with absent thyroid 
99m
Tc-MIBI uptake as 
group 1b. The patients in the second group were 
subdivided in the same manner. Anamnestic and 
laboratory data from the patients’ files were analysed 
in all patients. The laboratory tests were not 
performed at our institution. The data were evaluated 
with the methods of descriptive statistics. 
 
 
Results 
 
Thyroid 
99m
Tc-MIBI uptake in the early phase 
of parathyroid scintigraphy was absent in 26 patients 
from both groups. The rest of the patients, 129/147 in 
the first group with primary hyperparathyroidism and 
62/70 from the second group with secondary 
hyperparathyroidism had normal thyroid uptake of 
99m
Tc-MIBI in the early phase and complete washout 
of the tracer in the delayed planar images of 
parathyroid scintigraphy. Figure 1 presents a patient 
with normal uptake in the thyroid during parathyroid 
scintigraphy.  
 
Figure 1: Early-phase (A) and delayed phase: anterior view (B), right lateral 
(C), left lateral (D) planar images with 
99m
Tc-MIBI in a 42-year-old male 
patient referred for investigation of primary hyperparathyroidism. The PTH 
level was measured 890 pg/ml; plasma ionised calcium level was elevated 
3.87 mmol/L. The patient had no history of thyroid disease, TSH level was 
within the normal range 
 
Early-phase (A) image shows normal uptake 
of 
99m
Tc-MIBI in the thyroid gland and focus of 
increased activity in the lower pole of the left lobe. 
Delayed phase images (B; C; D) show normal 
clearance of 
99m
Tc-MIBI from the thyroid and 
persistence of the focal increased activity, a finding 
consistent with parathyroid adenoma. 
Concomitant thyroid disease was observed in 
35/129 patients (27.1%) with suspicion for primary 
hyperparathyroidism and 6/62 patients (9.7%) with 
chronic renal failure. The data regarding early thyroid 
99m
Tc-MIBI uptake, and the frequency of thyroid 
disease in both patients‘ groups are presented in 
Table 1.  
The most frequent thyroid disease in patients 
with primary hyperthyroidism and normal 
99m
Tc-MIBI 
thyroid uptake (group 1a) was nodular goitre in 19 
patients followed by hypothyroidism due to chronic 
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autoimmune thyroiditis (CAD) in 9 patients and 
euthyroid CAD in 5 patients.  
Table 1: Number of patients with absent and normal early 
99
Tc 
MIBI thyroid uptake in both groups with data on the 
presence/absence of thyroid disease 
Primary hyperthyroidism Secondary hyperthyroidism 
147 patients 70 patients 
Absent thyroid 
uptake 
Normal thyroid uptake Absent thyroid 
uptake 
Normal thyroid uptake 
18 (12.2%) 129 (87.8%) 8 (11.4%) 62 (88.6%) 
TD NTD TD NTD TD NTD TD NTD 
17 
(94%) 
1 
(6%) 
35 (27.1%) 94 
(72.9%) 
3 
(37.5%) 
5 
(62.5) 
6 
(9.7%) 
56 
(92.3%) 
TD thyroid disease; NTD no thyroid disease 
 
Only 2 patients had a history of Graves’ 
disease but were in remission when scintigraphy was 
performed. The cause of thyroid disease in group 2a 
was nodular goitre in 5 patients and CAD with 
hypothyroidism in 1 patient. The data presenting the 
type of thyroid disease in all patients’ groups are 
shown in Fig. 2. 
 
Figure 2: Thyroid diseases in all patients’ groups. TT-Total 
thyroidectomy; CAD-H Hypothyroid chronic autoimmune disease; 
CAD-EU Euthyroid chronic autoimmune disease; NG Nodular 
goitre; GD Graves disease 
 
The scan analysis showed that in the group of 
patients with primary hyperparathyroidism 18/147 
patients (12.24%) showed absent thyroid uptake 
(group 1b). Further analysis showed that 8 out of 18 
patients (44.4%) had previously performed 
thyroidectomy due to various reasons and their 
ultrasound revealed minimal to absent residual tissue 
in the thyroid bed. The rest of the patients except one 
had thyroid disease. Out of these 9 patients, 7 
patients had hypothyroidism due to chronic 
autoimmune thyroiditis. All 7 patients were on L-
thyroxine substitution therapy and had TSH level 
within normal range. This was the most frequently 
encountered thyroid disease 7/9 (77.77%), and the 
other patients had nodular goitre 2/7 (22.22 %). The 
ultrasound report in patients with autoimmune 
thyroiditis confirmed normal sized thyroid with non-
homogenous structure in 4 patients, while 3 patients 
had a small atrophic thyroid gland. Only one patient 
presented with completely normal thyroid ultrasound, 
thyroid pertechnetate scan and normal values for 
thyroid hormones and antiperoxidase antibodies and 
absent thyroid uptake of MIBI. The patient didn’t have 
a history of another chronic disease, nor was taking 
any medications or nutritional supplements. The 
characteristics of the patients in this group are 
summarised in Table 2. The scintigraphy results 
showed parathyroid adenoma or hyperplasia in 10 out 
of 18 patients. The laboratory tests collected from the 
patients’ files were not performed at the same 
institution and were frequently missing. Therefore, 
statistical analysis was not performed for these data. 
Table 2: Clinical, biochemical, ultrasonographic and 
scintigraphic data of patients with primary hyperthyroidism 
with diminished thyroid uptake  
Patient 
no. 
Gender 
Age 
(years) 
iPTH 
(pg/ml) 
Ca++ 
(mmol/L) 
Total Ca* 
(mmol/L) 
Thyroid US report TD 
Scintigraphy 
report 
1 F 38 140.1 1.43 
Normal sized thyroid with the 
isoechoic structure 
No TD Positive 
2 F 40 170.7 1.49 
Normal sized thyroid with isoechoic 
structure and an anechoic nodule 
in the right lobe with dimension 21 
mm 
NG Positive 
3 F 60 3295 3.64* 
Normal sized thyroid with isoechoic 
structure and a hypoechoic nodule 
in the right lobe with dimension 25 
mm 
NG Positive 
4 F 60 82.2 NA 
Small sized thyroid with the 
hypoechoic and inhomogeneous 
structure 
CAT-H Positive 
5 F 63 105.5 1.44 
Small sized thyroid with isoechoic 
and inhomogeneous structure with 
fibrotic septae 
CAT-H Negative 
6 F 66 331 2.9* 
Normal sized thyroid with 
hypoechoic and inhomogeneous 
structure with fibrotic septae 
CAT-H Positive 
7 F 52 183 NA 
Normal sized thyroid with 
hypoechoic and inhomogeneous 
structure with fibrotic septae 
CAT-H Positive 
8 F 57 520.2 1.61 
Normal sized thyroid with isoechoic 
and inhomogeneous structure with 
fibrotic septae and small 
circumscribed hypoechogenic 
lesions 
CAT-H Positive 
9 F 33 263 1.5 
Small sized thyroid with the 
isoechoic and inhomogeneous 
structure 
CAT-H Negative 
10 F 72 304 2.9* 
Normal sized thyroid with the 
isoechoic and inhomogeneous 
structure 
CAT-H Positive 
11 F 42 140.4 1.12 Absent thyroid gland TT Negative 
12 F 66 119 1.23 
Residual thyroid parenchyma in 
the right thyroid bed with 
dimension 7 mm 
TT Negative 
13 F 58 134 NA Absent thyroid gland TT Negative 
14 F 68 391.5 1.2 Absent thyroid gland TT Positive 
15 F 43 NA NA 
Residual thyroid parenchyma in 
the right thyroid bed 
TT Negative 
16 F 40 NA NA Absent thyroid gland TT Positive 
17 F 62 NA NA 
Residual thyroid parenchyma in 
the left thyroid bed 
TT Negative 
18 F 66 NA NA Absent thyroid gland TT Negative 
m: male; f: female; iPTH: intact parathyroid hormone; Ca
++
: plasma ionized calcium; * total 
plasma calcium level; NA: not available; US: ultrasound; TD: thyroid disease; NG: Nodular 
goiter; CAT-H: Hypothyroidism due to chronic autoimmune thyroiditis; TT: Total 
thyroidectomy; Scintigraphy report-Positive: presence of parathyroid 
adenoma/hyperplasia; Negative: absence of parathyroid adenoma/hyperplasia. 
 
Normal ranges for laboratory results: iPTH: 
12.0-65.0 pg/ml, Ca
++
: 1.12-1.32 mmol/L, Total 
plasma Ca: 2.10-2.16 mmol/L. In the group of patients 
with secondary hyperparathyroidism due to chronic 
kidney failure, 8 patients presented with absent 
thyroid uptake of MIBI in the thyroid phase of the 
scanning (Figure 3).  
From these patients (group 2b), 5 patients 
(7.1%) had normal thyroid ultrasound and no history 
of thyroid disease. The laboratory tests for thyroid 
function were within normal range. One of the patients 
had repeated scans, and both times the thyroid 
uptake was absent during the early phase. The other 
3 patients had hypothyroidism and were on L-
thyroxine substitution therapy with TSH level within 
normal range. All 5 patients had been on hemodialysis 
programme for more than 5 years (range 7-19 years, 
mean 12 ± 5.5), and had high levels of PTH 
(>1000pg/ml, mean 1889 ± 750.76). The data for 
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serum calcium and phosphate levels were not 
available in all patients. The patients’ data are 
presented in Table 3. 
 
Figure 3: Early-phase (A) and delayed phase: anterior view (B); right lateral 
(C); left lateral (D) planar images with 
99m
Tc-MIBI in a 45-year-old female 
patient with chronic renal failure who has been on hemodialysis treatment for 
9 years. The PTH level was measured 2500 pg/ml, and the patient had no 
history of thyroid disease. In both the early and the delayed images it was not 
possible to see any activity in the thyroid region, only higher uptake in the 
lower pole of the right lobe suggestive of parathyroid adenoma 
 
Data analysis showed that in our patients with 
chronic kidney failure 7.1% of patients had absent 
thyroid MIBI uptake in the early phase and no history 
of thyroid disease. The uptake on the early and late 
scans in the parathyroid lesions was visible in 4 
patients, while in one patient there was no uptake in 
thyroid or parathyroid lesion. After surgery in this 
patient, parathyroid hyperplasia was confirmed on 
histopathology. 
 
 
Discussion 
 
The early uptake and washout of MIBI in the 
thyroid gland can be affected by several factors. The 
most frequently encountered reason is the pathology 
of the thyroid gland. The increased uptake and slow 
washout in some thyroid nodules are well-established 
fact. This scintigraphy pattern was related with a 
higher probability of malignancy in several studies [7], 
but can also lead to difficulties in the interpretation of 
parathyroid scintigraphy especially in the departments 
where SPECT/CT is not available. Thyroid nodules 
can also have diminished uptake, although there are 
not many studies that were studying the early uptake 
5-10 minutes after injection. This pattern, found in 2 
patients in our study, is most probably due to 
degenerative changes in the nodule, although 
histology data was not available. The diminished 
thyroid uptake can also be attributed to other thyroid 
pathologies. There are several reports that connect 
the chronic thyroiditis with diminished MIBI uptake 
[8][9]. The study of Santos et al. was designed to 
estimate the thyroid MIBI uptake at a 5
th
 minute after 
injection in patients with different thyroid pathologies. 
The thyroid MIBI uptake was correlated to euthyroid 
patients referred for cardiac perfusion scintigraphy. 
This study reports reduced thyroid MIBI uptake in 
patients with atrophic Hashimoto thyroiditis, but higher 
uptake compared with euthyroid control group in 
patients with hypertrophic Hashimoto disease. The 
authors concluded that this kind of findings is probably 
due to glandular destruction and fibrosis in chronic 
atrophic thyroiditis [9]. Our study confirmed diminished 
uptake in 7 patients with hypothyroidism due to 
chronic autoimmune thyroiditis in patients with primary 
hyperparathyroidism, and in 3 patients with secondary 
hyperparathyroidism who had been diagnosed with 
hypothyroidism. The ultrasound was in concordance 
with normal sized or atrophic thyroid with signs of 
diffuse changes in the parenchyma. All patients were 
hypothyroid, with L-thyroxine substitution therapy at 
the time of MIBI scintigraphy. The administration of L-
thyroxine to suppress the thyroid was claimed by 
some authors to improve the sensitivity of parathyroid 
scintigraphy in primary hyperparathyroidism [10].  
 
Table 3: Clinical, biochemical, ultrasonographic and scintigraphic data of patients with chronic kidney failure with diminished 
thyroid uptake in the early phase of parathyroid scintigraphy 
Patient no. Gender Age (years) iPTH (pg/ml) 
Ca++ (mmol/L) 
Total Ca* 
(mmol/L) 
P (mmol/L) Thyroid US report TD Scintigraphy result 
HD duration 
(years) 
1 M 55 2830 NA NA 
Normal sized thyroid with the 
isoechoic structure 
No TD Positive 7 
2 F 59 1016 2.58 1.76 
Normal sized thyroid with 
isoechoic structure 
No TD Positive 8 
3 F 45 2500 1.10 2.18* 1.26 
Normal sized thyroid with 
isoechoic structure 
No TD Positive 9 
4 M 61 1500 NA NA 
Normal sized thyroid with the 
isoechoic structure 
No TD Positive 19 
5 M 53 1602 2.18 1.33 
Normal sized thyroid with the 
isoechoic structure 
No TD Negative 17 
6 F 65 88 2.5* 2.00 
Small sized thyroid with the 
isoechoic and inhomogeneous 
structure 
H Positive 18 
7 F 63 474.4 2.2 1.32 
Small sized thyroid with 
isoechoic, inhomogeneous 
structure and fibrotic septae 
H Positive 6 
8 F 66 1347 NA 2.2 
Small sized thyroid with 
isoechoic, inhomogeneous 
structure and fibrotic septae 
H Positive NA 
Abbreviations: m: male, f: female, iPTH: intact parathyroid hormone, Ca
++
: plasma ionized calcium, * total plasma calcium level, P: phosphorus, NA: not available, US: ultrasound, TD: 
thyroid disease, H: Hypothyroidism, HD: hemodialysis, Scintigraphy report: Positive: presence of parathyroid adenoma/hyperplasia; Negative: absence of parathyroid 
adenoma/hyperplasia Normal ranges for laboratory results: iPTH: 12.0-65.0 pg/ml, Ca
++
: 1.12-1.32 mmol/L, Total plasma Ca: 2.10-2.16 mmol/L, P: 0.80-1.40 mmol/L. 
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The TSH in our patients was in normal range; 
therefore we concluded that the reduced thyroid 
uptake was due to the parenchymal destruction rather 
than the L-thyroxin administration. Diminished thyroid 
MIBI uptake is well documented in patients with 
amiodarone-induced hyperthyroidism type 2 [11]. The 
possible pathophysiological mechanism for reduced 
MIBI uptake in this type of thyroiditis is the presence 
of apoptotic or necrotic processes involving 
mitochondrial membrane potential collapse in these 
patients. However, there were no patients with this 
kind of thyroid disruption in our patients. 
Thyroid diseases were almost the only cause 
of absent early thyroid MIBI uptake during parathyroid 
scintigraphy in our patients with primary 
hyperparathyroidism. Thyroid disease also caused for 
absent early thyroid MIBI uptake in 3 patients with 
secondary hyperparathyroidism. However, thyroid 
disease was also present in patients with normal early 
thyroid uptake (Table 1). The level of the damage to 
the thyrocytes and their mitochondrial content by 
thyroid disease is probably the factor that determines 
the 
99m
Tc-MIBI thyroid uptake. 
To the best of our knowledge, this is the first 
study that reports absent thyroid uptake in patients 
with chronic renal failure without thyroid disease 
during the early phase of parathyroid scintigraphy. 
This kind of altered MIBI distribution was reported in 
7.1% of patients in this group. Few studies have 
aimed to evaluate MIBI uptake in the thyroid gland 
during dual-phase parathyroid scintigraphy in patients 
with chronic renal failure. The study of Kiratli et al. 
evaluated the ratio between the ROI over thyroid and 
ROI over mediastinum in patients on hemodialysis 
with and without calcitriol supplementation, and in 
patients without renal disease but with high PTH 
levels and calcitriol supplementation. These study 
groups were compared with a control group of 
patients without parathyroid or renal disease referred 
for myocardial perfusion scintigraphy. All three groups 
of patients demonstrated significantly lower 
thyroid/mediastinum ratio compared to control group 
of patients [5]. The authors suggested the role of 
calcitriol supplementation considering that vitamin D 
receptors and its ligands have been recognised as 
factors that can influence the expression of P-
glycoprotein [12]. P -glycoprotein is well described 
cellular efflux pump for lipophilic compounds like MIBI. 
However, the level of P-glycoprotein in the normal 
thyroid of healthy individuals is not very high and is 
not considered a factor that influences the faster 
washout of MIBI from the thyroid compared with 
parathyroid adenomas [13]. Although it is possible that 
therapy with calcitriol in patients with chronic renal 
failure can up-regulate P-glycoprotein and induce very 
fast washout from the thyroid, the study of Kiratli et al., 
demonstrated lower MIBI thyroid uptake in 
hemodialysis patients that were not receiving calcitriol 
as well [5]. Therefore, lower thyroid MIBI uptake in this 
group of patients can also be attributed to the other 
factors that can influence the mitochondrial and 
plasma membrane potentials and mitochondrial 
content and function in the thyroid follicular cells. 
Although this study reported lower early thyroid MIBI 
uptake, they do not report absent uptake in their 
patients as we did in a small proportion of our 
patients. The semiquantitative evaluation was not 
performed in our study. Therefore it is possible that 
thyroid uptake was lower than in healthy patients in a 
larger percentage of patients in our study. 
However, not all studies in the literature report 
diminished thyroid MIBI uptake during the early phase 
of the parathyroid scintigraphy. Kandeel et al. report 
normal thyroid uptake in the early scan and 
appropriate wash out in their series of patients with 
the end-stage renal disease, although the number of 
patients was small and the thyroid uptake during 
parathyroid scintigraphy was not the aim of their 
research [14]. Our study found normal thyroid MIBI 
distribution during parathyroid scintigraphy in 88.6% of 
patients with chronic renal failure. Our study was 
retrospective and is missing a lot of information on 
laboratory results and therapy regimens in these 
patients. Therefore the mechanism underlying this 
altered distribution cannot be explained. Larger 
prospective studies might offer better insight on the 
biodistribution of 
99m
Tc-MIBI in patients with 
secondary hyperparathyroidism due to chronic renal 
disease. 
The most common cause of altered 
biodistribution of MIBI in the thyroid during parathyroid 
scintigraphy is thyroid disease. Thyroid surgery or 
chronic autoimmune thyroiditis with glandular 
destruction are the most common, although nodular 
goitre can alter the thyroid uptake of MIBI as well. The 
thyroid MIBI uptake can be very low in a small 
proportion of patients with chronic renal failure without 
any sign of thyroid disease. The causes for these 
findings in this group of patients are still unclear and 
need further investigation. Discovering the factors that 
influence the distribution of this radiopharmaceutical in 
the thyroid in these patients can lead to better 
understanding of the pathophysiology of the thyroid 
cell during chronic renal failure. 
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